跳转至内容
Merck
CN

主要文件

查看所有文档

P8828

培高利特 甲磺酸盐

≥98%, solid

别名:

8β-[(Methylthio)methyl]-6-propylergoline methanesulfonate salt, Pergolide methanesulfonate salt

登录 查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式（希尔记法）:
C19H26N2S · CH4O3S
化学文摘社编号:
66104-23-2
分子量:
410.59
NACRES:
NA.77
PubChem Substance ID:
24277927
UNSPSC Code:
12352200
MDL number:
MFCD00153859
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

assay

≥98%

form

solid

optical activity

[α]20/D −35°, c = 0.2 in pyridine(lit.)

color

white

solubility

ethanol: 2 mg/mL, DMSO: 5.2 mg/mL, H2O: insoluble

originator

Valeant

storage temp.

−20°C

SMILES string

CS(O)(=O)=O.[H][C@@]12Cc3c[nH]c4cccc(c34)[C@@]1([H])C[C@@H](CSC)CN2CCC

InChI

1S/C19H26N2S.CH4O3S/c1-3-7-21-11-13(12-22-2)8-16-15-5-4-6-17-19(15)14(10-20-17)9-18(16)21;1-5(2,3)4/h4-6,10,13,16,18,20H,3,7-9,11-12H2,1-2H3;1H3,(H,2,3,4)/t13-,16-,18-;/m1./s1

InChI key

UWCVGPLTGZWHGS-ZORIOUSZSA-N

Gene Information

human ... DRD1(1812), DRD2(1813), DRD3(1814), DRD4(1815), DRD5(1816)

Biochem/physiol Actions

Dopaminergic agonist; suppresses pituitary secretion of prolactin; anti-Parkinsonian agent.

Features and Benefits

This compound was developed by Valeant. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

pictograms

Skull and crossbones
GHS06

signalword

Danger

hcodes

H300

Hazard Classifications

Acute Tox. 2 Oral

存储类别

6.1B - Non-combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Faceshields, Gloves, type P3 (EN 143) respirator cartridges

法规信息

新产品

此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
SLBM6092V
SLBF6838V
070M2011V
070M2011
119K1638

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Nobuhiro Ooba et al.
Drug safety, 34(4), 329-338 (2011-03-23)
Use of the ergot-derived dopamine receptor agonists (cabergoline and pergolide) is associated with an increased risk of cardiac valvulopathy. Pergolide was withdrawn from the US market in 2007 because of the risk of valvular heart disease, while the European Medicines
Jos J Adam et al.
Neuroscience letters, 500(2), 113-117 (2011-06-28)
Using an anti-cue keypress task, we examined executive control in Parkinson's disease (PD) patients treated with deep brain stimulation (DBS) of the subthalamic nucleus (STN) and dopaminergic medication. Across sessions, we varied stimulation (on, off) and dopaminergic medication (on, off).
Sachiko Nakaoka et al.
Internal medicine (Tokyo, Japan), 50(7), 687-694 (2011-04-07)
The ergot-derived dopamine agonists, cabergoline and pergolide, are associated with valvulopathy risk. In Japan, product labels were revised in April 2007 to recommend periodic echocardiography for patients taking these dopamine agonists, however, the compliance of physicians to follow through with
查看所有相关文献